The ANKS1A Knockout A-549 Polyclonal Cells offer a CRISPR/Cas9-edited polyclonal population of human A-549 cells with targeted disruption of the ANKS1A gene. This heterogeneous pool contains diverse loss-of-function mutations, providing a biologically relevant tool for studying ANKS1A function without clonal selection bias. Its polyclonal nature ensures representation of the full spectrum of editing outcomes in a lung cancer model.
The parental A-549 cell line is an established human lung adenocarcinoma model derived from a 58-year-old male. It is widely employed to study lung cancer pathogenesis, epithelial barrier integrity, drug metabolism, and oncogenic signaling. These adherent cells exhibit characteristics of alveolar type II pneumocytes, providing a physiologically relevant platform for targeted gene knockout experiments.
ANKS1A encodes a scaffold protein that links activated Eph receptors (EphA4, EphB2) to downstream signaling cascades. Following ephrin stimulation, ANKS1A interacts with these receptors, facilitating activation of Rho GTPases (Rac1, Cdc42), non-receptor tyrosine kinases FAK and Src, and actin regulators such as cortactin and the WAVE complex. This scaffold coordinates actin cytoskeleton remodeling, focal adhesion dynamics, and cell migration. Additionally, ANKS1A modulates MAPK/ERK signaling, influencing transcriptional programs for adhesion and motility.
In A-549 cells, ANKS1A knockout disrupts ephrin-Eph receptor-mediated pro-migratory and invasive signaling. Loss of scaffold function impairs spatiotemporal organization of membrane signaling complexes, attenuating Rac1-driven lamellipodia formation and ERK-dependent gene expression. Consequently, this knockout model enables dissection of ANKS1A contributions to lung cancer cell dissemination, epithelial-to-mesenchymal transition, and metastatic progression, while also facilitating study of scaffold protein integration in epithelial tumor signaling.
Researchers can employ this polyclonal pool for western blot validation of ANKS1A loss and phospho-signaling (ERK1/2, FAK, Src), transwell migration/invasion assays, immunofluorescence staining of F-actin, co-immunoprecipitation of Eph receptor complexes, and RT-qPCR of downstream targets. These applications support validation of ANKS1A as a therapeutic target, investigation of Eph-ephrin signaling dynamics, and functional genomics screens in lung adenocarcinoma. For further information, please contact Ascent Research.
